Insulet (PODD) announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott (ABT) FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Insulet price target raised to $208 from $163 at Stifel
- Insulet Assumes New Off-Balance Sheet Financial Obligation
- Insulet Secures Lower Interest Rates in Credit Agreement Amendment
- Insulet recalls Omnipod 5 Android app over software error, FDA says
- Salesforce upgraded, Chipotle downgraded: Wall Street’s top analyst calls